Expert Interview
Insights on the potential of Edwards Lifescience and JenaValve’s Trilogy™ Transcatheter Heart Valve (THV) System for treating aortic regurgitation
Ticker(s): EW, JenavalveInstitution: UCLA Medical Center
- Interventional cardiologist at UCLA , Medical Director of the Structural Heart Disease Program & Associate Clinical Professor of Medicine at the David Geffen School of Medicine.
- Manages 25 patients with ATTR-CM.
- Areas of expertise include coronary artery disease and structural and valvular heart disease while specializing in complex percutaneous coronary interventions including the use of rotational atherectomy.
Roughly how many patients with aortic regurgitation do you currently manage?
Added By: dami_adminWhat unmet needs or challenges stand out to you when managing aortic regurgitation patients today?
Added By: dami_adminWhat factors typically influence your openness to adopting new valve technologies in the patient population?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
